BMEA 4.23 (+3.68%)
US09077A1060BiotechnologyBiotechnology

Biomea Fusion (BMEA) Stock Highlights

4.23 | +3.68%
2024-12-21 06:00:07
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companys lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Statistics

Range Today
3.96 4.28
Volume Today 858.6K
Range 1 Year
3.61 20.21
Volume 1 Year 255.26M
Range 3 Year
2.84 43.69
Volume 3 Year 485.41M
Range 10 Year
2.84 43.69
Volume 10 Year 510.44M

Highlights

Market Capitalization 296.43M (small)
Floating Shares 22.46M
Current Price 4.23
Price To Earnings -2.03
Price To Book 3.9
Earnings Per Share -4.01
Payout Ratio 0%

Performance

Latest +3.68%
1 Month -35.02%
3 Months -51.32%
6 Months -12.96%
1 Year -70.19%
3 Years -39.83%
5 Years -79.26%
10 Years -79.26%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.